Sobi gets EU nod for Doptelet in rare blood disorder ITPSweden’s Sobi has secured EU approval for Doptelet in primary chronic immune thrombocytopenia (ITP), an indication that the Share XSobi gets EU nod for Doptelet in rare blood disorder ITPhttps://pharmaphorum.com/news/sobi-gets-eu-nod-for-doptelet-in-rare-blood-disorder-itp/
Sobi stays on its acquisitive streak with $915m Dova dealSweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover Share XSobi stays on its acquisitive streak with $915m Dova dealhttps://pharmaphorum.com/news/sobi-stays-on-its-acquisitive-streak-with-915m-dova-deal/
